Millions of people now take GLP-1 receptor agonist drugs such as semaglutide and tirzepatide for weight loss and diabetes management, but a growing body of clinical evidence suggests these medications may come with an underappreciated cost: higher rates of bone loss, fractures, and tendon problems. A randomized trial of 64 adults at elevated fracture risk found that once-weekly semaglutide produced 6.8 kg more weight loss than placebo over 52 weeks while simultaneously increasing markers of bone resorption. Separate large-database analyses have linked tirzepatide to higher composite rates of osteoporosis and fragility fractures compared with other GLP-1 agents, raising questions about whether rapid drug-driven weight loss weakens the musculoskeletal system faster than it can adapt.
Why bone and tendon risks from GLP-1 drugs demand attention now
The core tension is straightforward. When a person loses weight quickly, the mechanical load on bones and tendons drops. Bone and connective tissue remodel slowly, often over months or years. If drug-assisted weight loss outpaces the body’s ability to recalibrate tissue strength, a window of vulnerability opens. That mismatch between reduced loading and ongoing tissue turnover could explain why fracture and tendon injury signals are appearing in clinical data tied to GLP-1 receptor agonists.
A phase 2 randomized trial published in eClinicalMedicine enrolled 64 adults without type 2 diabetes who already faced increased fracture risk. Participants received semaglutide 1.0 mg weekly or placebo for 52 weeks. The semaglutide group lost substantially more weight, with an estimated treatment difference of 6.8 kg versus placebo. But the trial also detected increased bone resorption markers and reductions in certain bone mass measures, a finding that complicates the otherwise positive metabolic profile of semaglutide.
This matters because the drugs are no longer niche prescriptions for diabetes. They are prescribed broadly for obesity, and many patients stay on them for years. If even a fraction of long-term users experience accelerated bone loss, the population-level impact on fractures could be significant, particularly among older adults and postmenopausal women who already carry elevated skeletal risk.
Tirzepatide, fracture signals, and tendon outcomes in large databases
A retrospective cohort study using the TriNetX federated health records network compared patients who started tirzepatide between June 2022 and May 2024 against those who initiated other GLP-1 receptor agonists during the same period. After propensity matching to control for baseline differences, the study found a higher risk for composite new-onset osteoporosis or fragility fracture among tirzepatide users relative to patients on other GLP-1 drugs. Because tirzepatide acts on both GLP-1 and GIP receptors and tends to produce greater weight loss than single-receptor agents, the finding raises the possibility that the magnitude of weight reduction itself drives skeletal harm.
Tendon-related outcomes present a more mixed picture. A TriNetX-based matched cohort study examining five-year shoulder outcomes, including atraumatic rotator cuff tears and shoulder fractures, in GLP-1 receptor agonist users versus comparators found signals worth tracking at that anatomical site. Yet a separate matched-cohort analysis reported no increase in postoperative complications after arthroscopic rotator cuff repair among GLP-1 users. Another propensity-matched national study examining Achilles tendon repair outcomes found that a history of GLP-1 receptor agonist use conferred no improvement in surgical results, suggesting the drugs neither helped nor clearly harmed tendon healing in that setting.
Taken together, these studies do not yet prove that GLP-1 drugs directly damage tendons. They do, however, indicate that the drugs are not protecting musculoskeletal tissue the way their anti-inflammatory properties might have suggested, and that certain skeletal endpoints, particularly osteoporosis and fragility fractures, appear to worsen with the most potent weight-loss agents in the class.
Gaps in surveillance and what patients should watch for
The FDA’s Adverse Event Reporting System, which covers spontaneous reports from 2004 to the present and is updated quarterly, provides the main pharmacovigilance backbone for tracking fracture, tendonitis, and rupture reports linked to any marketed drug. Clinicians and patients can also submit suspected adverse events through the agency’s MedWatch program. No dedicated safety communication specifically addressing musculoskeletal injuries from GLP-1 receptor agonists has been issued as of the available evidence reviewed here.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
